Quick Answer
MiNK Therapeutics, Inc. reported Net Income of -$12.49 million for fiscal year 2025.
MiNK Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$12.49M | -15.9% |
| 2024 | -$10.78M | +52.0% |
| 2023 | -$22.46M | +19.8% |
| 2022 | -$27.99M | +7.4% |
| 2021 | -$30.21M | -86.1% |
| 2020 | -$16.24M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.89M | -59.8% | +31.9% |
| June 30, 2025 | -$4.24M | -56.8% | -53.2% |
| March 31, 2025 | -$2.77M | +27.4% | -53.1% |
| September 30, 2024 | -$1.81M | +64.7% | +33.1% |
| June 30, 2024 | -$2.70M | +56.4% | +29.1% |
| March 31, 2024 | -$3.81M | +32.9% | +25.5% |
| September 30, 2023 | -$5.12M | +19.2% | +17.4% |
| June 30, 2023 | -$6.20M | -1.4% | -9.0% |
- MiNK Therapeutics, Inc. showed a decrease of -15.9% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, MiNK Therapeutics, Inc.’s net income has grown by 23.1% (from -$16.24 million to -$12.49 million).
- The most recent figure is from MiNK Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: